Madrigal Pharmaceuticals shares are trading higher after the company announced the FDA has accepted for review its NDA for resmetirom for the treatment of adult patients with NASH with liver fibrosis.
Portfolio Pulse from Benzinga Newsdesk
Madrigal Pharmaceuticals announced that the FDA has accepted for review its New Drug Application (NDA) for resmetirom, a treatment for adult patients with NASH with liver fibrosis. This news has led to a rise in the company's stock.
September 13, 2023 | 3:06 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Madrigal Pharmaceuticals' stock is trading higher following the FDA's acceptance of its NDA for resmetirom. This could indicate increased investor confidence in the company's potential.
The FDA's acceptance of Madrigal's NDA for resmetirom is a positive development for the company. It suggests that the drug has met preliminary criteria for safety and efficacy, which could lead to eventual approval. This news is likely to boost investor confidence in the company's potential, leading to a rise in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100